Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Citeron-1
- Development stage
- Unknown
- Lead developer
- Max Pharma
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
**Citeron-1** is a topical ophthalmic fixed-dose product marketed by Maxx Pharm as sterile eye drops containing hyaluronic acid 0.2% and citicoline monosodium salt 2%. Hyaluronic acid provides mucomimetic, mucoadhesive, and viscoelastic tear-film support to lubricate, hydrate, and protect the ocular surface, while citicoline is positioned as an ophthalmic neuroprotective component that supports restoration of cell-membrane integrity in degenerative ocular pathology. The product is used locally in ophthalmology, including for ocular irritation and as supportive treatment in glaucoma and other ocular-surface or degenerative eye conditions.
- Brand names
- Citeron 1Citeron1Citeron-1
Beyond the preview
Go deeper on Citeron-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Citeron-1.